Vanguard Russell 1000 Value Index Fund (VONV) Is At $105.03 Formed Wedge; 1 Analysts Bullish Pernix Therapeutics Holdings, Inc. (PTX)

Pernix Therapeutics Holdings, Inc. (NASDAQ:PTX) Logo

Among 4 analysts covering Pernix Therapeutics (NASDAQ:PTX), 1 have Buy rating, 0 Sell and 3 Hold. Therefore 25% are positive. Pernix Therapeutics had 9 analyst reports since August 7, 2015 according to SRatingsIntel. The firm earned “Buy” rating on Friday, August 7 by Brean Capital. The stock has “Market Outperform” rating by JMP Securities on Wednesday, September 9. On Tuesday, February 9 the stock rating was maintained by Brean Capital with “Buy”. Oppenheimer downgraded the stock to “Perform” rating in Thursday, March 17 report. The stock of Pernix Therapeutics Holdings, Inc. (NASDAQ:PTX) has “Hold” rating given on Friday, March 11 by Needham. Needham maintained the stock with “Strong Buy” rating in Friday, August 7 report. Brean Capital maintained the stock with “Buy” rating in Friday, March 11 report. The stock has “Hold” rating by Brean Capital on Friday, August 12. See Pernix Therapeutics Holdings, Inc. (NASDAQ:PTX) latest ratings:

Vanguard Russell 1000 Value Index Fund (VONV) formed wedge down with $100.83 target or 4.00% below today’s $105.03 share price. Vanguard Russell 1000 Value Index Fund (VONV) has $2.84B valuation. The stock decreased 0.43% or $0.45 during the last trading session, reaching $105.03. About 11,233 shares traded. Vanguard Russell 1000 Value Index Fund (NASDAQ:VONV) has risen 4.33% since April 25, 2017 and is uptrending. It has underperformed by 7.22% the S&P500.

The stock increased 1.73% or $0.04 during the last trading session, reaching $2.35. About 22,423 shares traded. Pernix Therapeutics Holdings, Inc. (NASDAQ:PTX) has declined 41.49% since April 25, 2017 and is downtrending. It has underperformed by 53.04% the S&P500.

Pernix Therapeutics Holdings, Inc., a specialty pharmaceutical company, focuses on the acquisition, development, and commercialization of prescription drugs primarily for the United States market. The company has market cap of $27.90 million. It targets underserved therapeutic areas, such as central nervous system , including neurology, pain, and psychiatry. It currently has negative earnings. The companyÂ’s products comprise Treximet, a fixed dose combination product indicated for the treatment of acute migraine; Zohydro ER with BeadTek, an opioid agonist indicated for the management of pain; and Silenor, a non-narcotic, non-scheduled, and non-addictive prescription sleep aid for the treatment of insomnia characterized by difficulty with sleep maintenance.